Table 3 Clinicopathological features selection using the univariable and multivariate Cox logistic regression model among the training group.

From: Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial–mesenchymal transition

Variables

Univariate analysis

Multivariate analysis

Hazard ratio

95% CI*

p-value

Hazard ratio

95% CI*

p-value

Age (years)

1.131

1.028–1.954

0.045

1.089

0.922–1.317

0.058

BMI (kg/m2)

1.016

0.969–1.064

0.514

Tumor size (cm)

1.271

1.014–1.298

0.048

0.933

0.815–1.069

0.314

Menopausal status

 Pre/peri-menopause

Reference

Reference

 Post-menopause

1.153

1.037–1.209

0.047

3.498

0.196–6.374

0.394

Fertility history

 0–1

Reference

 ≥ 2

0.989

0.967–1.025

0.574

Pathological grade

 G1–2

Reference

Reference

 G3

1.509

1.031–4.506

0.034

1.382

1.104–3.965

0.041

FIGO stage

 I–II

Reference

Reference

 III–IV

2.534

1.293–4.966

0.007

2.391

1.230–4.377

0.011

Lymph node metastasis

 Negative

Reference

Reference

 Positive

1.269

1.045–3.582

0.036

1.312

1.029–2.975

0.039

Ascites

 Negative

Reference

Reference

 Positive

1.123

1.042–1.301

0.017

1.215

1.067–1.806

0.026

CTC counts (n/5 mL)

1.241

1.108–1.384

0.009

1.187

1.098–1.752

0.012

M-CTC (n %)

1.147

1.051–1.288

0.006

1.098

1.047–1.320

0.009

E-CTC (n %)

0.983

0.857–2.694

0.148

Hybrids-CTC (n %)

1.058

0.894–1.753

0.365

Neutrophil (109/L)

1.015

0.992–1.038

0.207

Lymphocyte (109/L)

1.066

0.888–1.278

0.494

Platelet (109/L)

1.002

0.997–1.007

0.351

Albumin (g/L)

0.909

0.849–0.972

0.025

1.027

0.980–1.077

0.266

CA-125 (U/mL)

1.101

1.002–1.203

0.019

1.097

1.021–1.373

0.028

CA-199 (U/mL)

0.977

0.942–1.012

0.198

AFP (ng/mL)

1.001

0.963–1.040

0.958

CEA (ng/mL)

1.001

0.999–1.012

0.805

HE4 (pmol/L)

1.217

1.104–1.232

0.039

0.959

0.850–1.081

0.489

  1. BMI Body Mass Index, FIGO the International Federation of Gynecology and Obstetrics, CTC circulating tumor cell, M-CTC mesenchymal CTCs/ total CTCs percentage, E-CTC epithelial CTCs/ total CTCs percentage, Hybrids-CTC hybrids CTCs/ total CTCs percentage, CA-125 carbohydrate antigen-125, CA-199 carbohydrate antigen-199, CEA carcinoembryonic antigen, AFP alpha-fetoprotein, HE4 human epididymis protein 4.